secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001193125-23-053843
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea reports Q4 2022 net loss of $34.4M; provides clinical updates on COVID-19, HCV, and dengue programs
--------------------------------------------------------------------------------

- Net loss of $34.4M ($0.41 loss per share) in Q4 2022 vs net income of $117.1M in Q4 2021; full year 2022 net loss $115.9M.
- Revenue $0 in Q4 and full year 2022 vs $192.2M and $351.4M in 2021 due to end of Roche collaboration.
- Cash and marketable securities $646.7M at Dec 31, 2022, down from $764.4M at Dec 31, 2021.
- Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 continues enrollment; interim analysis expected 2H23.
- Dengue program deprioritized; Phase 2 HCV combination trial to start enrollment in 2Q23 with initial results by 4Q23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312523053843/0001193125-23-053843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312523053843/d462845d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-053843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer